Tasimelteon for insomnia

Bibliography

• National Institutes of Health. State of the science conference statement on manifestations and management of chronic insomnia in adults. Sleep 2005;28:1049-57
   PubMed Web of Science ®Google Scholar
• Roth T. Insomnia: definition, prevalence, etiology, and consequences. J Sleep Med 2007;3(Suppl):S7-10
   Google Scholar
• American Psychiatric Association. Sleep Disorders. In: Diagnostic and statistical manual of mental disorders: diagnostic criteria for primary insomnia. 4th edition. Text revision. American Psychiatric Association, Washington, DC; 2000. p. 597-661
   Google Scholar
• American Academy of Sleep Medicine. International Classification of Sleep Disorders. 2nd edition. Diagnostic and Coding Manual. American Academy of Sleep Medicine, Westchester, IL; 2005
   Google Scholar
• World Health Organization. The ICD-10 Classification of Mental and Behavioral Disorders. World Health Organization, Geneva, Switzerland; 2002
   Google Scholar
• Dogramji K. The epidemiology and diagnosis of insomnia. Am J Manag Care 2006;12:S214-20
   PubMed Web of Science ®Google Scholar
• National Sleep Foundation. 2005 sleep in America poll. National Sleep Foundation, Washington, DC; 2005
   Google Scholar
• Ohayon M. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev 2002;6:97-111
   PubMed Web of Science ®Google Scholar
• Sateia J, Doghramji K, Hauri P, Evaluation of chronic insomnia: an American Academy of Sleep Medicine review. Sleep 2000;23:243-308
   PubMed Web of Science ®Google Scholar
• Winokur A, Gary K, Rodner S, Depression, sleep physiology and antidepressant drugs. Depress Anxiety 2001;14(1):19-28
   PubMed Web of Science ®Google Scholar
• Van Cauter E, Knutson K. Sleep and the epidemic of obesity in children and adults. Eur J Endocrinol 2008;159(Suppl 1):S59-66
   PubMed Web of Science ®Google Scholar
• Ancoli-Israel S. The impact and prevalence of chronic insomnia and other sleep disturbances associated with chronic illness. Am J Manag Care 2006;12(8 Suppl):S221-9
   PubMed Web of Science ®Google Scholar
• Smith S, Sullivan S, Hopkins W, Douglas J. Frequency of insomnia reports in patients with obstructive sleep apnea hypopnea syndrome (OSAHS). Sleep Med 2004;5(5):449-56
   PubMed Web of Science ®Google Scholar
• Brower K. Insomnia, alcoholism and relapse. Sleep Med Rev 2003;7(6):523-39
   PubMed Web of Science ®Google Scholar
• Ancoli-Israel S. The impact and prevalence of chronic insomnia and other sleep disturbances associated with chronic illness. Am J Manag Care 2006;12(8 Suppl):S221-9
   PubMed Web of Science ®Google Scholar
• Breslau N, Roth T, Rosenthal L, Andreski P. Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of your adults. Biol Psychiatry 1996;39(6):411-18
   PubMed Web of Science ®Google Scholar
• Rosekind M, Gregory K. Insomnia risks and costs: health, safety, and quality of life. Am J Manag Care 2010;16(8):617-626
   PubMed Web of Science ®Google Scholar
• Miyamoto M. Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders. CNS Neurosci Ther 2009;15:32-51
   PubMed Web of Science ®Google Scholar
• Scharf M, Lankford A. Melatonin receptor agonists: ramelteon and melatonin. In: Sadock B, Sadock V, Ruiz P, editors, Comprehensive Textbook of Psychiatry. 9th edition. Lippincott Williams & Wilkins, Philadelphia; 2009;3145-51
   Google Scholar
• Pagel J, Parnes B. Medications for the treatment of sleep disorders: an overview. Prim Care Comp J Clin Psychiatry 2001;3(3):118-25
   PubMedGoogle Scholar
• Weber J, Siddiqui M, Wagstaff Q, McCormack P. Low-dose doxepin: in the treatment of insomnia. CNS Drugs 2010;24(8):713-20
   PubMed Web of Science ®Google Scholar
• Estelle G, Simons R. H1-receptor antagonists: safety issues. An Allergy Asthma Immunol 1999;83:481-8
   PubMed Web of Science ®Google Scholar
• Ringdahl E, Pereira S, Delzell J. Treatment of primary insomnia. J Am Board Fam Pract 2004;17:212-19
   PubMedGoogle Scholar
• Rajaratnam S, Middleton B, Stone B, Melatonin advances the circadian timing of EEG sleep and directly facilitates sleep without altering its duration in extended sleep opportunities in humans. J Physiol 2004;561(Pt 1):339-51
   PubMed Web of Science ®Google Scholar
• Arendt J. Melatonin: characteristics, concerns, and prospects. J Biol Rhythms 2005;20:291-303
   PubMed Web of Science ®Google Scholar
• Arendt J, Rajaratnam S. Melatonin and its agonists: an update. Br J Psychiatry 2008;193:267-9
   PubMed Web of Science ®Google Scholar
• Dkene D, Lockley W, Arendt J. Use of melatonin in the treatment of phase shift and sleep disorders. Adv Exp Med Biol 1999;467:79-84
   PubMed Web of Science ®Google Scholar
• Kamei Y, Hayakawa T, Urata J, Melatonin treatment for circadian rhythm sleep disorders. Psychiatry Clin Neurosci 2000;54:391-496
   Web of Science ®Google Scholar
• Pandi-Perumal S, Srinivasan V, Poeggeler B, Drug insight: the use of melatonergic agonists for the treatment of insomnia – focus on ramelteon. Nat Clin Pract Neurol 2007;3:221-8
   PubMedGoogle Scholar
• Brzezinski A, Vangel M, Wurtman, Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev 2005;9:41-50
   PubMed Web of Science ®Google Scholar
• Buscemi N, Vandermeer G, Hooton N, Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis. Br Med J 2006;332:385-93
   PubMed Web of Science ®Google Scholar
• Neubaeur D. A review of ramelteon in the treatment of sleep disorders. Neuropsychiatr Dis Treat 2008;4(1):69-79
   PubMedGoogle Scholar
• EMEA. Questions and answers on recommendation for the refusal of the marketing authorization for ramelteon. Press Release, May 30, 2008. Available from: http://www.emea.suropa.eu/pdfs/human/opinion/Ramelteon_26821608en.pdf
   Google Scholar
• Wade A, Downie S. Prolonged-release melatonin for the treatment of insomnia in patients over 55 years. Expert Opin Investig Drugs 2008;17(10):1567-72
   PubMed Web of Science ®Google Scholar
• Lemoine P, Nir T, Laudon M, Zisapel N. Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects. J Sleep Res 2007;16:372-80
   PubMed Web of Science ®Google Scholar
• Wade A, Ford I, Crawford G, Efficacy of prolonged release melatonin in insomnia patients aged 55-80 years: quality of sleep and next-day alertness outcomes. Curr Med Res Opin 2007;23:2597-605
   PubMed Web of Science ®Google Scholar
• Luthringer R, Muzet M, Zisapel N, Staner L. The effect of prolonged release melatonin on sleep measures and psychomotor performance in elderly patients with insomnia. Int Clin Psychopharm 2009;24:239-49
   PubMed Web of Science ®Google Scholar
• Reiter R. Melatonin: the chemical expression of darkness. Mol Cell Endocrinol 1991;79(1):63-72
   Google Scholar
• Arendt J, Skene D. Melatonin as a chronobiotic. Sleep Med Rev 2005;9:25-39
   PubMed Web of Science ®Google Scholar
• Hardeland R. Melatonin: signaling mechanisms of a pleiotropic agent. Biofactors 2009;35:183-92
   PubMed Web of Science ®Google Scholar
• Hardeland R. New approaches in the management of insomnia: weighing the advantages of prolonged release melatonin and synthetic melatoninergic agonists. Neuropsychiatr Dis Treat 2009;5:341-54
   PubMed Web of Science ®Google Scholar
• Rajaratnam S, Polymeropoulos M, Fisher D, Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomized controlled multicenter trials. Lancet 2009;373:482-91
   PubMed Web of Science ®Google Scholar
• Vachharajani N, Yeleswaram K, Boulton D. Preclinical pharmacokinetics and metabolism of BMS-214778, a novel melatonin receptor agonist. J Pharm Sci 2003;92:760-72
   PubMed Web of Science ®Google Scholar
• Rajaratnam S, Polymeropoulos M, Fisher D, Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomized controlled multicenter trials. Available from: www.lancet.com: published online December 2, 2008:Webappendix. [Last accessed 11 April 2011]
   Google Scholar
• Hardeland R. Investigational melatonin receptor agonists. Expert Opin Investig Drugs 2010;19(6):747-64
   PubMed Web of Science ®Google Scholar
• Feeney J, Birznieks G, Scott C, Melatonin agonist tasimelteon improves sleep in primary insomnia characterized by difficulty falling asleep. Sleep 2009;32(Suppl): abstract 43
   Google Scholar
• Karasek M. Melatonin, human aging, and age-related diseases. Exp Gerontol 2004;39:1723-9
   PubMed Web of Science ®Google Scholar
• Mitkus S, Birzneiks G, Thompson A, Lavedan D. Effect of a period 3 (PER3) gene polymorphism on response to tasimelteon treatment in a phase advance model of transient insomnia. Sleep 2009;32(Suppl):A284
   Google Scholar
• Morgenthaler T, Lee-Chiong T, Alessi C, Practice parameters for the clinical evaluation and treatment of circadian rhythm sleep disorders. An American Academy of Sleep Medicine report. Sleep 2007;30(11):1445-59
   PubMed Web of Science ®Google Scholar
• Hardeland R. Melatonin, hormone of darkness and more – occurrence, control mechanisms, actions and bioactive metabolites. Cell Mol Life Sci 2008;65:2001-18
   PubMed Web of Science ®Google Scholar
• Ferguson A, Rajarathnam S, Dawson D. Melatonin agonists and insomnia. Expert Rev Neurother 2010;10(2):305-18
   PubMed Web of Science ®Google Scholar